Vascular Diseases  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
NCT01329289: SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Withdrawn
2
0
US
SOM230, Pasireotide, Bortezomib, Velcade, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, dexamethasone sodium phosphate, dexamethasone acetate
University of Pittsburgh, Novartis
Multiple Myeloma in Relapse, Multiple Myeloma
02/12
02/12
NCT01234974: IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Withdrawn
2
0
US
Pasireotide, Pasireotide s.c., Pasireotide LAR, SOM230, Everolimus, RAD001
Milton S. Hershey Medical Center
Multiple Myeloma
12/12
12/13

Download Options